Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07055480 Gene Therapy in Adult Males with Moderately Severe to Severe Hemophilia A
KCT0005828Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Feb 2021
- Countries
- 1
- Sponsor
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Conditions
- hemophilia A
01
Overview
Phase 3, open-label, single-arm trial of giroctocogene fitelparvovec in hemophilia A, sponsored by Pfizer. Planned start Feb 2021; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
PF-07055480 gene therapy arm
Single-arm, open-label treatment with PF-07055480 in adult male participants with moderately severe to severe hemophilia A.
03
Who it enrols
Adult male patients with moderately severe to severe hemophilia A (factor VIII activity ≤1%) are eligible; healthy volunteers are not included.
Beyond the preview
Go deeper on KCT0005828.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005828.